patients who underwent tumor resection, the resected specimen also was assessed to determine the concordance between the FNA and surgical specimens. RESULTS: In the primary PanNET cohort of 65 FNAs, ALT was detected in 15 specimens (23%). Although all ATRX-negative and DAXX-negative tumors were ALT-positive, 3 of 14 (21%) ALT-positive tumors did not exhibit nuclear loss of either ATRX or DAXX. The ALT-positive tumors were associated with larger radiographic size (4.9 vs 2.4 cm, on average; P < .05) and higher grade (P < .05). Overall, there was 100% concordance in ALT status and ATRX/DAXX immunohistochemistry results between the FNA and surgical specimens. CONCLUSIONS: Both ALT and loss of ATRX/DAXX can be accurately performed on FNA specimens with adequate material. Because ALT is a fundamental mechanism of pathogenesis, the ability to determine ALT in small biospecimens has implications for the design of clinical trials.
INTRODUCTION
Pancreatic neuroendocrine tumors (PanNETs) are the second most common malignancy of the pancreas, and the 10-year survival rate of patients with this disease is only 40%.
1,2 Although PanNETs have an incidence of approximately 1 per 100,000 individuals per year, incidence in the United States has been increasing, perhaps because of better detection techniques. 3 In addition to prevalent mutations in the menin (MEN1) gene, previous whole exome sequencing studies revealed that 45% of PanNETs harbored mutually exclusive, inactivating mutations in either a thalassemia-mental retardation, X linked (ATRX), or death domain-associated protein 6 (DAXX).
(eg, promoters and enhancers), H3.3 localization to telomeres appears to be independent of HIRA. 5 In contrast, the ATRX/DAXX complex deposits histone variant H3.3 in repetitive, heterochromatic chromosomal regions, in particular at telomeres and pericentromeric regions. [5] [6] [7] We previously established an association between the somatic inactivating mutations in either ATRX or DAXX and the presence of the alternative lengthening of telomeres (ALT) pathway, which is a telomerase-independent mechanism to maintain telomere lengths. 8 Whereas most cancers maintain their telomeres through activation of the enzyme telomerase, telomere maintenance in ALT-positive cancers is mediated through homology-directed DNA repair. 9, 10 Recent studies have demonstrated that, compared with ALT-negative and ATRX/DAXX-intact tumors, ALT-positive and ATRX/DAXX-negative primary PanNETs tend to be larger in size, have a higher World Health Organization grade, and are more likely to develop lymph node and distant metastases. [11] [12] [13] ALT is a critical mechanism of carcinogenesis in PanNETs; and, as such, our ability to evaluate the status of these biomarkers will aid in the design of future clinical trials. For example, emerging data in other tumor types have demonstrated that ALT positivity and/or ATRX loss confers in vitro sensitivity to radiation as well as inhibition of topoisomerase and the DNAdamage mediator ATR (a serine/threonine protein kinase). 14, 15 These early findings suggest that selected PanNETs may also share a similar sensitivity to these therapeutic strategies. Because fine-needle aspiration (FNA) is a noninvasive way to sample tumors, we evaluated whether we could accurately detect the presence of ALT and ATRX/DAXX loss in FNAs from a cohort of primary PanNETs. In a subset of patients who underwent tumor resection, we also evaluated the resected specimens to determine the concordance between the FNA and the surgical specimen.
MATERIALS AND METHODS

Case Selection
After approval from the Institutional Review Board for a waived-consent retrospective data review, the pathology database at the Johns Hopkins Medical Institutions was searched for all preoperative FNA cytology cases between 2005 and 2016. All cases were acquired either under transabdominal or endoscopic ultrasound-guided FNA with onsite evaluation of adequacy. Each identified case was reviewed, and the diagnosis was confirmed. Cases in which the cell block or subsequent levels contained more than 100 cells were included; those with fewer cells did not contain sufficient material for the appropriate biomarker analysis.
ATRX and DAXX Immunohistochemistry
Immunohistochemistry (IHC) was performed on formalin-fixed, paraffin-embedded tissue sections from cell block preparations from either FNA or surgical resection specimens. Immunolabeling for ATRX was performed using an anti-ATRX antibody (HPA001906; SigmaAldrich, St. Louis, Mo;1:100 dilution). The labeling was performed in the Ventana Benchmark XT autostainer (Ventana Medical Systems, Oro Valley, Ariz) using CC1 antigen-retrieval buffer for 30 minutes at 958C, incubation with primary antibody for 32 minutes, and detection with Ventana UltraView Universal diaminobenzidine. In contrast, immunolabeling for DAXX was performed as previously described 8, 13 using an anti-DAXX antibody (HPA008736; Sigma-Aldrich; 1:100 dilution). Briefly, tissue sections were deparaffinized, hydrated in xylene, and serially diluted in ethanol. For antigen retrieval, sections were steamed with citrate buffer for 30 minutes and then blocked against endogenous peroxidase activity with dual endogenous enzyme-blocking agent (Dako, Carpinteria, Calif) for 10 minutes. Sections were incubated with primary antibody (1:100 dilution) for 2 hours at room temperature followed by secondary antibody (Leica Microsystems, Wetzlar, Germany) for 30 minutes and detected with 3,30-diaminobenzidine (Sigma-Aldrich). Sections were counterstained with hematoxylin, rehydrated, and mounted. Only nuclear labeling was evaluated for ATRX and DAXX. Cases were scored as negative for ATRX or DAXX if nuclear expression was completely lost (despite retaining cytoplasmic expression) and adequate internal positive controls were present.
Telomere-Specific Fluorescence in Situ Hybridization
Deparaffinized slides were hydrated, steamed for 25 minutes in citrate buffer (Vector Laboratories, Burlingame, Calif), dehydrated, and hybridized with an indocarbocyanine (Cy3)-labeled peptide nucleic acid probe complementary to the mammalian guanine-rich telomere repeat sequence (N-terminus to C-terminus; Cy3-CCCTAACCCTAACCCTAA), as previously described. 8, 13, 16 An Alexa Fluor-488-labeled peptide nucleic acid probe specific to human centromeric DNA repeats for the centromere protein B (CENP-B) binding sequence (N-terminus to C-terminus; Alexa Fluor-488 ATTCGTTGGAAACGGGA) was included in the hybridization solution as a positive control for hybridization efficiency (ThermoFisher Scientific, Waltham, Mass). After posthybridization washes, the slides were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI). Slides were imaged with a Nikon 50i epifluorescence microscope equipped with X-Cite series 120 illuminator (EXFO Photonics Solutions Inc, Ontario, Calif) and appropriate fluorescence excitation/emission filters. Grayscale images were captured using Nikon NIS-Elements software and an attached Photometrics CoolsnapEZ digital camera (Nikon Inc, Melville, NY). Images were pseudocolored and merged.
Characteristics of ALT-positive tumors in fixed tissue specimens include dramatic cell-to-cell telomere length heterogeneity and the presence of large, ultrabright nuclear foci of telomere fluorescence in situ hybridization (FISH) signals marking ALT-associated telomeric DNA in interphase nuclei. 8, 17 Therefore, cases were visually assessed and classified as ALT-positive if ultrabright nuclear foci of telomere FISH signals were present in the cancer cells. The total intensities of individual ALT-associated, ultrabright nuclear foci have been previously measured as >10-fold higher than the mean integrated signal intensities for individual nonneoplastic cells in the same cases.
8,13,17
Statistical Analysis
Data were summarized using descriptive statistics (counts and frequencies for categorical variables, means and ranges for continuous variables). Fisher exact tests were used to compare the distribution of categorical variables between groups. Student t tests were used to test differences in means between groups. Disease-specific survival for each patient was calculated as the length of time from the date of diagnosis to the date of last follow-up or death. Patients who died from causes other than their PanNET disease were censored at their time of death. We estimated survival curves using the Kaplan-Meier method, and differences in the survival distributions between groups were tested using log-rank tests.
For patients who did not undergo resection, stage was estimated ("estimated stage") based on radiographic size and the presence or absence of metastases. An estimated stage 1A was defined as tumors with radiographic size <2 cm and no synchronous or metachronous metastasis. One case fit these criteria but was called pathologic T1 (pT2) on resection and thus was considered stage 1B. Similarly, we estimated tumor grade ("estimated grade") based on the Ki67 proliferation index as observed on the cell block material when a tumor was not resected, except in 2 instances in which the material on cell block was overtly high grade. If Ki67 had not been previously assessed on a specimen, then we did not estimate tumor grade for that case. The Ki67 proliferation index was estimated as the percentage of neoplastic cells that demonstrated nuclear positivity for Ki67 under light microscopy without digital device assistance.
We fit univariate and multivariate Cox proportional hazards models to quantify hazard ratios associated with the covariates of interest and death. Two-tailed P values < .05 were considered statistically significant. All analyses were performed using R version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Clinicopathologic Characteristics
The clinicopathologic characteristics of the 65 patients included in the study are provided in Table 1 . The mean age at the time of diagnosis was 59 years (range, 23-84 years), and 51% of patients were women. The mean radiographic size of tumors at the time of diagnosis was 3 cm (range, 0.4-14.5 cm), and 55% of tumors were located in the pancreatic body or tail. The tumor grade was known or was estimated in a total of 53 neoplasms, 70% were classified as grade 1, and the remaining 16 tumors were grade 2 or higher. Of the 65 patients, 29 (45%) underwent surgical resection. There was excellent correlation (r) between gross size and radiographic size at the time of diagnosis (r 5 0.87). Fourteen patients (22%) presented with unresectable disease and died within 1 year of the FNA diagnosis; 5 of those patients received chemotherapy or radiation. In contrast, 10 patients (15%) did not have subsequent follow-up records at our institution or documentation of death in the Social Security Index. At the time this study was completed, 14 patients (22%) had not undergone surgical resection and continued to receive surveillance. Almost 90% of patients had a nonfunctional
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PanNET, and 11% had an established, functional Pan-NET (n 5 7). On the basis of radiologic tumor size and the presence of metastasis, the tumor stage was known or estimated as either stage 1A (n 5 37; 60%) or stage 1B or higher (n 5 24; 40%).
Expression of ATRX and DAXX Correlates With ALT Activation
The results of immunolabeling for ATRX and DAXX and of the telomere-specific FISH for ALT are displayed in Figure 1 . Four specimens contained only enough residual material for FISH; in these cases, the expression of ATRX and DAXX could not be assessed. Loss of nuclear ATRX expression was identified in 6 FNA samples (10%), and loss of nuclear DAXX expression was identified in 5 additional FNAs (8%). All specimens that had ATRX loss were associated with intact DAXX labeling, and vice versa; therefore, in total, 11 cases had loss of nuclear ATRX or DAXX expression (18%). ALT was detected in 15 specimens (23%). Whereas all ATRX-negative and DAXXnegative tumors were ALT-positive, we identified 3 of 14 ALT-positive tumors (21%) in which both ATRX and DAXX remained intact. These 3 cases represent smaller tumors (3.0 cm), whereas 1 patient had MEN1 syndrome, and another had a synchronous metastasis. Of these, 1 tumor was resected (grade 2), another tumor was Abbreviations: ALT, alternative lengthening of telomeres; ATRX, a thalassemia-mental retardation, X linked; DAXX, death domain-associated protein 6. a This P value indicates statistical significance. b Sufficient data were not available in some instances to definitively determine the tumor location (1 patient), synchronous metastases (1 patient), and metachronous metastases (2 patients). c Estimated grade includes specimens in which tumor grade was estimated based on the Ki67 proliferation in cell block material when the tumor was not surgically resected.
predicted to be grade 1 based on FNA material, and the third tumor did not have a Ki67 index to allow grade prediction. Within the entire cohort, ALT-positive tumors were associated with larger radiographic size (4.9 vs 2.4 cm, on average; P < .05) and higher grade (P < .05). Similarly, ATRX/DAXX-negative tumors were associated with larger radiographic size (4.8 vs 2.3 cm, on average; P < .05) and higher known or estimated grade (P < .05). We did not observe significant associations between the presence of ALT or ATRX/DAXX loss and patients' age, sex, race, tumor functionality, location, or stage (Table 1) .
Correlation With Surgical Resection Specimens
Among 29 surgical resection specimens, 20 could be evaluated by IHC for ATRX and DAXX, and 21 could be evaluated for ALT by telomere-specific FISH. Overall, 100% concordance (21 of 21) was observed on telomerespecific FISH for ALT between cytology and surgical pathology; 16 negative specimens were called negative on resection, and 5 positive specimens were called positive on resection. We also observed 100% concordance between ATRX/DAXX IHC on cytology and surgical pathology. Specifically, ATRX had 100% concordance (20 of 20)
between the 2 specimen types; 3 negative specimens were called negative/heterogeneous on resection, and 17 positive specimens were called positive on resection (1 was not evaluated on resection). In addition, DAXX had 100% concordance (20 of 20); 2 negative specimens were called negative on resection, and 18 positive specimens were called positive on resection (1 was not evaluated on resection). An example of the concordance between the FNA and corresponding resected case is provided in Figure 2 .
Survival Outcomes and Prognostic Factors
The mean follow-up in this cohort was 21 months (median, 10.2 months; range, 0-132 months). In total, 12 patients died during follow-up, of which 11 deaths were from disease-specific causes. Estimated disease-specific survival rates at 1 year and 2 years were 82% (95% confidence interval [CI], 72%-94%) and 78% (95% CI, 67%-92%), respectively. We assessed the prognostic significance of clinical and pathologic covariates by comparing the survival distributions between groups of interest using log-rank tests and quantified effects using univariate Cox proportional hazards models. We observed that higher grade tumors, advanced primary tumor (pT) classification, overall stage (stage 1B or higher vs 1A), perineural invasion, and lymph node and synchronous metastases were each associated with decreased survival (Table 2) , as expected. Surgical resection was associated with a survival advantage (hazard ratio, 0.091; 95% CI, 0.01-0.71).
In this cohort, ALT status and ATRX/DAXX labeling were not prognostic of survival among the subset of patients undergoing surgical resection. Multivariate analyses were limited by the small number of observed deaths in our cohort. 
DISCUSSION
FNA is an important, minimally invasive method for obtaining diagnostic material from patients who present with a pancreatic mass. The material is often sufficient for ancillary molecular testing, which is becoming increasingly important to guide presurgical or nonsurgical management in a variety of patients, including patients with unresectable tumors, those planning for neoadjuvant therapy, and those undergoing surveillance of small tumors as part of conservative management. Although the evaluation of ALT among PanNET resection specimens has previously been described, [11] [12] [13] this is the first study to examine the use of telomere-specific FISH to determine ALT status on FNA specimens. Analysis of ALT on FNA specimens may help clinicians identify which small, low-grade tumors should be resected or monitored through surveillance. It is noteworthy that, because telomere maintenance through ALT activation is a fundamental mechanism of carcinogenesis, identifying ALT-positive PanNETs will become increasingly important in the design of clinical trials for new targeted therapies, including small molecules that may target the ALT pathway. 14, 15 One limitation of FNA is that the small sampling may be discordant with the corresponding larger surgical resection sample. FNA may sample only certain areas of heterogeneous tumors, causing results that may differ from what is observed in the final resection specimens. For instance, Ki67 proliferation indices may be discordant in PanNETs. 18, 19 Here, we observed no discordance between 21 FNA and resection specimen pairs for ALT analysis. In addition, no discordance was observed between 20 FNA and resection specimen pairs for ATRX and DAXX IHC. However, a previous study of resected specimens identified PanNETs with intratumoral heterogeneity by observing heterogeneous staining patterns of ALT and loss of ATRX or DAXX, suggesting the potential for misclassifying the tumor status based on FNA biomarker results alone.
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Finally, although validation studies are needed, telomerespecific FISH for ALT may be a more ideal assay, because 21% (3 of 14 cases) of the ALT-positive tumors maintained nuclear expression of ATRX and DAXX, suggesting that nuclear protein expression may not always mirror the mutational status of the gene (eg, missense mutations). 8, 11, 12 In summary, we have established that both ATRX/ DAXX IHC and telomere-specific FISH can be accurately performed on FNA specimens to reliably assess ALT status, as long as the cell block material used for analysis is adequate. In many instances, dedicated passes for cell block preparations are already performed once tumor cells are identified during onsite evaluation. This practice allows for the performance of ancillary studies, including neuroendocrine markers (eg, synaptophysin and chromogranin) and Ki67 analysis. Consequently, we conclude that ATRX/ DAXX IHC and telomere-specific FISH can be reliably performed in FNA specimens to determine ALT status early in the diagnostic evaluation, and this testing may be useful in the design of clinical trials.
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